anti-TIGIT antibody
Showing 1 - 25 of >10,000
Advanced Solid Tumor Trial in Bengbu (HB0030 injection)
Recruiting
- Advanced Solid Tumor
- HB0030 injection
-
Bengbu, Anhui, Chinathe First Affiliated Hospital of Bengbu Medical College
Jan 20, 2023
Advanced Malignancies Trial in Beijing (IBI939, IBI939+ Sintilimab)
Active, not recruiting
- Advanced Malignancies
- IBI939
- IBI939+ Sintilimab
-
Beijing, ChinaPeking University Cancer Hospital & Institute
Oct 4, 2022
Locally Advanced or Metastatic Solid Tumors, NSCLC Trial in Australia (HLX301)
Recruiting
- Locally Advanced or Metastatic Solid Tumors
- Non-small Cell Lung Cancer
-
Blacktown, New South Wales, Australia
- +4 more
May 25, 2022
Endometrial Tumors, Ovarian Cancer, Solid Tumor Trial in United States (COM701 in combination with BMS-986207 and nivolumab.)
Recruiting
- Endometrial Neoplasms
- +3 more
- COM701 in combination with BMS-986207 and nivolumab.
-
Chicago, Illinois
- +8 more
Aug 8, 2022
Advanced Tumors Trial in Guangzhou (JS006 as Monotherapy, JS006 in combination with Toripalimab)
Recruiting
- Advanced Tumors
- JS006 as Monotherapy
- JS006 in combination with Toripalimab
-
Guangzhou, Guangdong, ChinaSun Yat-Sen University Cancer Center
Sep 21, 2021
Advanced Tumor Trial (PM1009 injection)
Not yet recruiting
- Advanced Tumor
- PM1009 injection
- (no location specified)
Nov 7, 2022
Advanced Solid Tumours Trial (PM1021, PM8001)
Not yet recruiting
- Advanced Solid Tumours
- PM1021, PM8001
- (no location specified)
Sep 12, 2022
Esophageal Squamous Cell Carcinoma Trial in Worldwide (Tislelizumab, Ociperlimab, Placebo)
Recruiting
- Esophageal Squamous Cell Carcinoma
- Tislelizumab
- +2 more
-
Hefei, Anhui, China
- +85 more
Aug 19, 2022
Intrahepatic Cholangiocarcinoma Trial in Shanghai (GP+PD-1+Tight)
Withdrawn
- Intrahepatic Cholangiocarcinoma
-
Shanghai, Shanghai, ChinaZhongshan hospital, Fudan University
Mar 22, 2022
Solid Tumor, Adult Trial in Albury (Tiragolumab, Atezolizumab)
Not yet recruiting
- Solid Tumor, Adult
- Tiragolumab
- Atezolizumab
-
Albury, New South Wales, Australia
- +1 more
Aug 22, 2023
Evan Syndrome, Treatment Trial in Tianjin (Anti-CD38 antibody Injection)
Recruiting
- Evan Syndrome
- Treatment
- Anti-CD38 antibody Injection
-
Tianjin, Tianjin, ChinaChinese Academy of Medical Science and Blood Disease Hospital
Aug 25, 2023
NSCLC Trial in Worldwide (Atezolizumab, Tiragolumab, Placebo)
Active, not recruiting
- Non-small Cell Lung Cancer
- Atezolizumab
- +2 more
-
Tempe, Arizona
- +40 more
Nov 11, 2022
Stage IIIA Hepatocellular Carcinoma Trial (Radiotherapy combined with TKI and Anti-PD-1 Antibody)
Not yet recruiting
- Stage IIIA Hepatocellular Carcinoma
- Radiotherapy combined with TKI and Anti-PD-1 Antibody
- (no location specified)
Sep 24, 2023
Antiphospholipid Syndrome, Thrombocytopenia Trial in Tianjin (Anti-CD38 antibody Injection)
Recruiting
- Antiphospholipid Syndrome
- Thrombocytopenia
- Anti-CD38 antibody Injection
-
Tianjin, Tianjin, ChinaChinese Academy of Medical Science and Blood Disease Hospital
Aug 9, 2023
Safety and Efficacy Trial in Suzhou (Basiliximab, Vedolizumab)
Recruiting
- Safety and Efficacy
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Sep 27, 2023
Pancreatic Ductal Adenocarcinoma, Refractory NSCLC Trial in Washington (Daratumumab, KRAS vaccine, Nivolumab)
Not yet recruiting
- Pancreatic Ductal Adenocarcinoma
- Refractory Non-Small Cell Lung Cancer
- Daratumumab
- +2 more
-
Washington, District of ColumbiaGeorgetown Lombardi Comprehensive Cancer Center
Sep 1, 2023
Paroxysmal Nocturnal Hemoglobinuria Treated With Anti-C5
Completed
- Paroxysmal Nocturnal Hemoglobinuria
- Anti-C5 antibody treatment
-
Paris, FranceAP-HP Hôpital Saint Louis
Apr 24, 2023
The Effecacy and Safety of Humanized CD25 Antibody in aGVHD Prophylaxis Among Elderly Patients After HID-HSCT Trial (CD25
Not yet recruiting
- The Effecacy and Safety of Humanized CD25 Antibody in aGVHD Prophylaxis Among Elderly Patients After HID-HSCT
- CD25 prophylaxis
- (no location specified)
Jun 20, 2023